Yuvezzi — A Carbachol/Brimonidine Solution for Presbyopia
The Medical Letter on Drugs and Therapeutics · 25.05.2026 · 68 (1755) · 84-85
DOI: 10.58347/tml.2026.1755b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 25.05.2026.
Abstract (Originalsprache)
The FDA has approved Yuvezzi (Tenpoint), an ophthalmic solution containing the cholinergic agonist carbachol 2.75% and the alpha-adrenergic receptor agonist brimonidine 0.1%, for treatment of presbyopia. Carbachol and brimonidine have been available in single-ingredient ophthalmic solutions for other indications for years.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Yuvezzi — A Carbachol/Brimonidine Solution for Presbyopia. The Medical Letter on Drugs and Therapeutics, 68(1755), 84-85. https://doi.org/10.58347/tml.2026.1755b
Vancouver
Yuvezzi — A Carbachol/Brimonidine Solution for Presbyopia. The Medical Letter on Drugs and Therapeutics. 2026;68(1755):84-85. doi:10.58347/tml.2026.1755b
BibTeX
@article{euvimed2026,
title = {Yuvezzi — A Carbachol/Brimonidine Solution for Presbyopia},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1755},
pages = {84--85},
doi = {10.58347/tml.2026.1755b}
}
EUVIMED